Conduit Pharmaceuticals, Inc. is a disease agnostic life science company providing an efficient model for compound development. The company acquires assets that are Phase II-ready and seeks exits through third-party license deals following successful clinical trials.

Conduit Pharmaceuticals

Conduit Pharmaceuticals | 152 followers on LinkedIn. multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development

Dave Tapolczay

Partner at Thompson Hine LLP (Corporate & Securities) - Co-Chair of Public Companies Group, Chair Life Sciences Industry | Group Board Member

Faith Charles, JD

Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

CDT

COM:CONDUITPHARMA

Conduit Pharmaceuticals

Last Close

0.11

22/11 21:00

Market Cap

21.78M

Beta: -

Volume Today

23.25M

Avg: -

Analysis Not Available